Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Chlodantane and Dihexa — mechanism, dosing, side effects, legal status, and pricing.
Chlodantane (ADK-910) is a non-peptide aryl-substituted 2-aminoadamantane amide, structurally related to bromantane and classified in Soviet pharmacological literature as an actoprotector/adaptogen. It has never been approved for human use in any jurisdiction and remains entirely unevaluated in clinical trials. All available data derive from animal and cell-culture experiments conducted in the former Soviet Union.
Dihexa (PNB-0408) is a small-molecule hexapeptide-like analog of angiotensin IV developed at Washington State University by the Harding/Wright group as a preclinical candidate for Alzheimer's disease and cognitive decline. It is NOT FDA-approved and has never been tested in human clinical trials. The often-quoted claim that it is 'roughly ten million times more potent than BDNF' refers to EC50 comparisons in an in vitro dendritic spine assay, not clinical efficacy.
Chlodantane
Dihexa
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Chlodantane
No pricing data yet.
Check Chlodantane prices →Dihexa
COA corpus from Disclosed Labs — independently tested batches only.
Chlodantane
1
COAs
99.9%
Avg purity
1
Labs
Dihexa
4
COAs
99.1%
Avg purity
4
Labs
No human data exist; a 2012 review explicitly states that all pharmacological data derive from animal or cell-culture experiments, with no clinical research conducted. In unspecified animal models, chlodantane enhanced resistance to physical and toxic-chemical stressors, produced immunostimulating effects in stress-induced immunodeficiency, and protected against hypoxia, high and low ambient temperature, and toxic chemical challenge. Effects were reported to appear after a single administration, and immunostimulant activity was described as more pronounced than that of bromantane.
McCoy et al. (J Pharmacol Exp Ther 2013, PMID 23055539) is the original dihexa characterization: oral dihexa reversed scopolamine-induced memory deficits and improved Morris water maze performance in aged rats at low doses. Sun et al. (Brain Sci 2021, PMID 34827486) reported that dihexa rescued cognitive impairment in the APP/PS1 Alzheimer's mouse via PI3K/AKT signaling, with increased synaptophysin and reduced neuroinflammation. Wright & Harding (J Alzheimers Dis 2015, PMID 25649658) reviewed the brain HGF/c-Met system as an Alzheimer's target. Note: Benoist et al. (JPET 2014, PMID 25187433), which reported the HGF/c-Met-dependent synaptogenesis mechanism, was retracted in 2025 and should not be relied on as primary evidence. The 'roughly seven orders of magnitude more potent than BDNF' descriptor refers to in vitro dendritic spine EC50 values, not clinical efficacy. Dihexa has never entered human clinical trials; Athira Pharma's related analog fosgonimeton failed its Phase 2/3 LIFT-AD Alzheimer's endpoint in 2024 and was discontinued, after which Athira shifted focus to ATH-1105 for ALS.
Chlodantane (Performance) and Dihexa (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs